Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CK-3773274 in symptomatic obstructive hypertrophic cardiomyopathy (Phase 3, China)
CTR20221835Phase 3Completed
- Sponsor
- Cytokinetics
- Start
- Jul 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of aficamten in hypertrophic cardiomyopathy (HCM), sponsored by Cytokinetics. Started Jul 2022; status: completed.
02
Drugs
aficamten
03
Conditions
hypertrophic cardiomyopathy (HCM)
Beyond the preview
Go deeper on CTR20221835.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20221835.